Gritstone Oncology Inc

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Gritstone Oncology reports strong financials and promising advancements in immunotherapy

Gritstone Oncology Inc showcases financial stability, progress in cancer immunotherapy, and advancements in infectious disease programs. Challenges include data requirements for ongoing studies, while opportunities lie in upcoming data presentations and exploring novel vaccine concepts.

Gritstone Oncology excels in Q1 with promising GRANITE program and samRNA advancements

Gritstone Oncology's Q1 2023 earnings call highlighted strong financials, progress in the GRANITE program, and advancements in the samRNA platform. Challenges include endpoint selection for Phase 3 study and managing pseudo progressors. Opportunities lie in combining immunotherapies for KRAS mutations and exploring adjuvant settings.

Gritstone Oncology reports positive Q1 results and eyes market expansion

Gritstone Oncology's Q1 2024 performance showcased positive outcomes in the GRANITE program and financial stability through strategic funding.
The company's strengths lie in promising immune responses, encouraging PFS data, and a proactive approach to clinical program advancement.
Challenges include data gaps in patient groups and uncertainties around future consortium data, while opportunities abound in market expansion and upcoming data releases.
Overall, Gritstone Oncology's focus on innovative cancer vaccine programs and financial prudence positions them well for future growth and clinical success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 121.74% and 1223.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Gritstone Oncology, Inc. (GRTS) Q1 Earnings and Revenues Top Estimates

EMERYVILLE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the first quarter ended March 31, 2021 and reviewed business highlights.

Gritstone Reports First Quarter 2021 Financial Results and Business Highlights

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced it is changing its name to Gritstone bio, Inc. effective immediately.

Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus

Pfizer

Regeneron Pharmaceuticals

3 Top Coronavirus Stocks to Buy Right Now

– Preliminary Data from Phase 1 Study of CORAL Expected Mid-year –

Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC

Ocugen, Inc.

Zomedica

Could These 3 Stocks Be 10-Baggers in 2021?

Applied Molecular Transport

Moderna

Here's why these highfliers could have more fuel in the tank.

3 Biotech Stocks That Have Already Rocketed Higher in 2021

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 0.00% and 12.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

EMERYVILLE, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2020 and reviewed business highlights.

Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

EMERYVILLE, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced two promotions within its leadership team. Karin Jooss, Ph.D., previously the company's executive vice president of research and chief scientific officer, has been appointed to the position of head of research and development. Erin Jones, M.S., who served as the company's executive vice president of global regulatory affairs and quality, has been appointed to the position of chief operating officer (COO).

Gritstone Announces Promotions Within its Leadership Team

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gritstone Oncology, Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Abbott Labs

RedHill Biopharma

Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.

4 Top COVID Stocks to Buy in February

Gilead Sciences announced a partnership in HIV with Gritstone Oncology, and upped its stake in Arcus Biosciences. Biotech stock Arcus jumped, but Gritstone fell at the stock market's close.

Biotech Stock Gritstone Stumbles On Gilead Tie-Up, While Arcus Pops

Gilead Sciences

FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead's efforts to find a curative treatment for human immunodeficiency virus (H

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure

Gritstone Oncology (GRTS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Gritstone Oncology (GRTS)

Netflix

Bank of America

Lumentum Holdings

Progress Software

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Bank of America and Netflix

Wall Street analysts with solid track records like Netflix, these other stocks into February

The coronavirus presents one big risk in the future. This vaccine maker is tackling it.

Is This Under-the-Radar COVID Stock the Next Moderna?

Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.

Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up

— Deal provides nonexclusive access to Genevant's leading LNP technology for use in Gritstone's self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 —

Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

The stock price of Gritstone Oncology Inc (NASDAQ: GRTS) has increased by 248.51%. This is why it happened.

GRTS Stock Price Increases 248.51%: Why It Happened

Aclaris Therapeutics

Celyad

Merus

Minerva Neurosciences

Tenax Therapeutics

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV (NASDAQ: MRUS) announced a R&D collaboration and licensing agreement with large-cap pharma Eli Lilly And Co (NYSE: LLY) for developing up to three CD-engaging T-cell redirecting bispecific antibody therapies for oncology indications.

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

Gritstone's COVID-19 vaccine may have a critical role to play in halting the ongoing pandemic.

Why Gritstone Oncology Is Bolting Higher Today

--Gritstone to Host Conference Call Today at 8:00 a.m. ET-- EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it is advancing development of a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants. Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have entered into a clinical trial agreement to initiate clinical testing. A Phase 1 clinical trial, expected to be conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), is in development. The Bill & Melinda Gates Foundation (Gates Foundation) is supporting the preclinical evaluation of the vaccine.

Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2

--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing-- --Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the closing of the previously announced $110 million private investment in public equity (PIPE) financing, as well as a newly executed PIPE financing for an additional $15 million in gross proceeds resulting from the sale of shares of its common stock at a price per share of $3.71. Gross proceeds from the two PIPE financings total $125 million, before deducting placement agent fees and offering expenses. The PIPE financings are supported by a consortium of high quality new and existing institutional investors with expertise in health care, including Redmile Group, Avidity Partners, EcoR1 Capital, BVF Partners L.P. and Versant Ventures.

Gritstone Oncology Announces Private Placement Financings Totaling $125 Million

EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement to raise gross proceeds of $110 million resulting from the sale of shares of its common stock and/or pre-funded warrants through a private investment in public equity (PIPE) financing at a price per share of $3.34. The financing was led by certain existing and new investors, Redmile Group, Avidity Partners and EcoR1 Capital.

Gritstone Oncology Announces $110 Million Private Placement

News for Gritstone Oncology Inc Stock (GRTS)